Treatment Registry

Company

Hers

Hers publishes oral semaglutide, brand semaglutide and brand tirzepatide, from $149 to $1,899 a month.

  • 5 programs
  • 3 molecules
  • 10 readings

Read from forhers.com on September 3, 2026. This page records what the company publishes. It is not a review and takes no position on the company.

Go to Hers

Visit Hers

We earn nothing from this link. Hers has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.

What it costs

Oral semaglutideOral tablet$298

first month, including the required fees on record · ◯ $149 advertised · Wegovy Pill

Brand semaglutideInjection, pen$348

first month, including the required fees on record · ◯ $199 advertised · Wegovy Pen

Brand tirzepatideInjection, pen$448

first month, including the required fees on record · ◯ $299 advertised · Zepbound KwikPen

Brand tirzepatideInjection, vial$448

first month, including the required fees on record · ◯ $299 advertised · Zepbound Vial

first month, including the required fees on record · ◯ $1,899 advertised · Mounjaro

Terms

PharmacyApostrophe Pharmacy LLC; XeCare LLC; EHT Pharmacy LLC dba Curexa; CD Pharmacy LLC dba Red Rock Pharmacy; AnazaoHealth Corporation; Strive Specialties, Inc.
MembershipRequired, $149 per month. An active Hers Weight Loss Membership is required ($39 for the first month, auto-renews at $149/month thereafter). Membership is billed separately and does not include or guarantee a prescription. Medication is not available without a membership.
StatesNot disclosed

Not yet checked: consultation fee.

Terms can differ between this company’s programs; each entry carries its own.

Programs

EntryProviderFormPer month
at its shortest term		Link
TR-0123HersOral tablet$149
Wegovy Pill		Record
TR-0124HersInjection, pen$199
Wegovy Pen		Record
TR-0125HersInjection, pen$299
Zepbound KwikPen		Record
TR-0126HersInjection, vial$299
Zepbound Vial		Record
TR-0127Hers$1,899
Mounjaro		Record

Notes

Recorded against this company rather than one program.

September 2, 2026

  1. 1. Foundayo (orforglipron, $149/mo) is also sold here but doesn't match any of this register's six `drug` values (not semaglutide/tirzepatide/liraglutide), so it is omitted from `entries` rather than misclassified. Zepbound and Mounjaro also appear at a flat $1,899/mo with no dose or form stated, alongside the dose-based $299/mo Zepbound Vial/KwikPen listings just above them — the page never explains why the $1,899 figures are so much higher; possibly an un-discounted list price shown without qualification.

Before you act

Cite this

Treatment Registry. (2026). Hers: recorded programs and prices. Last verified September 3, 2026. Retrieved [your access date], from https://treatmentregistry.com/providers/hers